CLINICAL TRIALS PROFILE FOR BRUKINSA
✉ Email this page to a colleague
All Clinical Trials for Brukinsa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03145064 ↗ | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | Completed | BeiGene | Phase 2 | 2017-06-30 | Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis. |
| NCT03332017 ↗ | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | Active, not recruiting | BeiGene | Phase 2 | 2017-11-15 | The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma. |
| NCT03336333 ↗ | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | Recruiting | BeiGene | Phase 3 | 2017-11-02 | To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival. |
| NCT04002297 ↗ | Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma | Recruiting | BeiGene | Phase 3 | 2019-08-21 | This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Brukinsa
Condition Name
| Condition Name for Brukinsa | |
| Intervention | Trials |
| Small Lymphocytic Lymphoma | 3 |
| Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | 2 |
| Refractory Transformed B-cell Non-Hodgkin Lymphoma | 2 |
| Diffuse Large B-cell Lymphoma | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Brukinsa
Trials by Country
Clinical Trial Progress for Brukinsa
Clinical Trial Phase
Clinical Trial Sponsors for Brukinsa
Sponsor Name
